Home » Posts tagged with » Oncology
Elicio raises $33m to advance lymph node-targeted immuno-therapies

Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

Varian introduces Ethos therapy – AI-powered cancer care delivery solution

Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news. Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and […]

Continue reading …
Equashield CSTD now available for oncology nurses in Japan

US medical device company Equashield through Japanese distributor Tosho has entered into an exclusive agreement with IV tube manufacturer PAL Medical to provide Equashield’s Closed System Transfer Devices (CSTDs) to oncology nurses in Japan. Post agreement, Tosho will provide PAL Medical with Equashield’s closed IV connectors to develop safer IV sets for oncology nurses administering […]

Continue reading …
BioMed, University of California open cancer research center in San Diego

The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]

Continue reading …
Valo Therapeutics licenses PeptiENV technology from the University of Helsinki

Valo Therapeutics (Valo Tx) has licensed proprietary PeptiENV technology from Helsinki University that is designed to facilitate the coating of enveloped viruses with antigens associated with tumour. The Finnish immuno-oncology company, which is a spin-out company from the Finland-based University of Helsinki, is focused on developing tumour antigen-coated oncolytic viruses as therapeutic vaccines. Previously, Valo […]

Continue reading …
MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

Continue reading …
Boehringer Ingelheim, MD Anderson to advance new cancer treatments

German pharmaceutical giant Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center are joining forces to form a new virtual research and development center (R&D center) to rapidly advance new cancer treatments, covering various forms of the disease including lung and gastrointestinal cancers. The new virtual R&D center is expected to facilitate the […]

Continue reading …
Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

Continue reading …
PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial

PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]

Continue reading …
Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

Continue reading …
Page 1 of 7123Next ›Last »